Medicus Pharma (NASDAQ:MDCX) is a clinical stage holding company focused on investing in and accelerating novel life sciences and biotechnology companies.
Skinject, Inc., a wholly owned subsidiary of Medicus Pharma, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell and squamous cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The company currently has an FDA approved phase 2 trial actively recruiting patients.
Executive Interviews
Medicus Pharma receives UAE approval for Phase 2a Endometriosis trial
Executive Interviews
Medicus Pharma cleared by FDA for registrational Phase 2b trial in patients with Gorlin Syndrome
